Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma
نویسندگان
چکیده
منابع مشابه
B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
PURPOSE Multiple myeloma is a usually incurable malignancy of plasma cells. New therapies are urgently needed for multiple myeloma. Adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a promising new therapy for hematologic malignancies, but an ideal target antigen for CAR-expressing T-cell therapies for multiple myeloma has not been identified. B-cell maturation antigen ...
متن کاملAdvancing Chimeric Antigen Receptor-Engineered T-Cell Immunotherapy Using Genome Editing Technologies: Challenges and Future Prospects
Chimeric antigen receptor engineered-T (CAR-T) cells also named as living drugs, have been recently known as a breakthrough technology and were applied as an adoptive immunotherapy against different types of cancer. They also attracted widespread interest because of the success of B-cell malignancy therapy achieved by anti-CD19 CAR-T cells. Current genetic toolbox enabled the synthesis of CARs ...
متن کاملChimeric antigen receptor T-cell immunotherapy tackles blood cancers.
intervention studies, assess change, and establish relationships with theoretically relevant factors and clinically important outcomes such as mortality. " The instrument has a broad content coverage, [has] very high reliability, and is strongly linked to self-confidence about engaging in health decisions, " Dumenci said. Completing CHLT-30 takes 10–15 minutes , and the score reflects the numbe...
متن کاملChimeric Antigen Receptor (CAR) T-Cell Therapy.
Surgery, chemotherapy, and radiation therapy have been the foundation of cancer treatment. Advances in the field of immunology (a branch of science that studies all aspects of the immune system) have led to a greater understanding of the ways in which the body’s own defenses can be used for treatment of blood cancers. Cancer researchers are now studying how the immune system can help destroy ca...
متن کاملEngineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor
Background: Recently, modification of T cells with chimeric antigen receptor (CAR) has been an attractive approach for adoptive immunotherapy of cancers. Typically, CARs contain a single-chain variable domain fragment (scFv). Most often, scfvs are derived from a monoclonal antibody of murine origin and may be a trigger for host immune system that leads to the T-cell clearance. Nanobody is a spe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Hematology
سال: 2019
ISSN: 0939-5555,1432-0584
DOI: 10.1007/s00277-018-03592-9